Kalundborg, Denmark
Novo Nordisk began construction in May of 2015 on a $223 million pharmaceutical manufacturing facility in Kalundborg, Denmark. The 81,000-sf project will support the production of active pharmaceutical ingredients for hemophelia treatments. The plant is expected to be fully operational by 2020.
